Reply to Chris R. Cardwell, Samy Suissa and Liam J. Murray's Letter to the Editor re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså,

European Urology

Volumn 64, Issue 1, 2013, Pages

  Grytli, Helene Hartvedt ^a   Fagerland, Morten Wang ^a   Fosså, Sophie D ^a,b   Taskén, Kristin Austlid ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

CANCER PATIENT; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; DISEASE ASSOCIATION; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; LETTER; LIFE EXPECTANCY; NORWAY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SOCIAL SECURITY;

ADRENERGIC BETA-ANTAGONISTS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84878939258     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.045     Document Type: Letter

References (2)

1. Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007.
2. Z. Zhou, E. Rahme, M. Abrahamowicz, and L. Pilote Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods Am J Epidemiol 162 2005 1016 1023